Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study

Background Secukinumab demonstrated superior efficacy to ustekinumab at week 4 and week 16 of the CLEAR study, with comparable safety, in subjects with moderate-to-severe plaque psoriasis. Objective To compare the efficacy and safety of secukinumab and ustekinumab use over 52 weeks. Methods Analysis...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American Academy of Dermatology 2017-01, Vol.76 (1), p.60-69.e9
Hauptverfasser: Blauvelt, Andrew, MD, MBA, Reich, Kristian, MD, Tsai, Tsen-Fang, MD, Tyring, Stephen, MD, PhD, Vanaclocha, Francisco, MD, Kingo, Külli, MD, PhD, Ziv, Michael, MD, BSc, Pinter, Andreas, MD, Vender, Ronald, MD, FRCPC, Hugot, Sophie, MSc, You, Ruquan, MSc, Milutinovic, Marina, MD, Thaçi, Diamant, MD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Secukinumab demonstrated superior efficacy to ustekinumab at week 4 and week 16 of the CLEAR study, with comparable safety, in subjects with moderate-to-severe plaque psoriasis. Objective To compare the efficacy and safety of secukinumab and ustekinumab use over 52 weeks. Methods Analysis of 52-week data from CLEAR, a randomized, double-blind, phase 3b study. Results Among 676 randomized subjects, secukinumab demonstrated superiority to ustekinumab at week 52 in the proportion of subjects with ≥90% improvement in Psoriasis Area and Severity Index (PASI 90) (76% vs 61% [ P  
ISSN:0190-9622
1097-6787
DOI:10.1016/j.jaad.2016.08.008